NINDS BIOMARKERS IN MULTIPLE SCLEROSIS STUDY (BIOMS)

多发性硬化症研究中的 NINDS 生物标志物 (BIOMS)

• 批准号: 7608473
• 负责人: CARLO S TORNATORE
• 金额: $ 2.63万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608473
• 关键词: Biological Markers; Clinical; Computer Retrieval of Information on Scientific Projects Database; Funding; Gene Proteins; Goals; Grant; Haplotypes; Institution; Link; Magnetic Resonance Imaging; Molecular Profiling; Multiple Sclerosis; Patients; Phenotype; Relapse; Research; Research Personnel; Resources; Single Nucleotide Polymorphism; Source; United States National Institutes of Health; cohort; protein expression

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The "MS-CombiRx trial" is an ongoing study supported by NINDS. Its goal is to identify biomarkers (by gene- and protein expression profiling, single nucleotide polymorphism (SNP) haplotype determination, HLA typing) and link these with clinical- and MRI phenotypes in a large cohort (1000) of relapsing remitting (RR-) MS patients and to examine how these biomarkers distinguish MS patients and healthy, matched controls.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 “MS-CombiRx试验”是一项由NINDS支持的正在进行的研究。其目标是确定生物标志物（通过基因和蛋白质表达谱，单核苷酸多态性（SNP）单倍型测定，HLA分型），并将其与复发缓解（RR-）MS患者的大型队列（1000）中的临床和MRI表型联系起来，并检查这些生物标志物如何区分MS患者和健康匹配的对照组。